Successful results of 5-year test data opens potential opportunity for long-term recording applications for Parkinson's disease, epilepsy, spinal cord stimulation, neurological disorders, and research markets.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it successfully completed initial pre-clinical long-term testing of recording capabilities on its platform thin film electrode technology. In test procedures, the electrodes' ability to record electrical activity over a span of 5 years was measured using an accelerated aging test model. The test results demonstrated NeuroOne's thin film electrodes' reliability against environmental factors that may contribute to device failure or malfunction, which is a well-established challenge with thin film electrode technology.
https://finance.yahoo.com/news/neuroone-medical-technologies-corporation-releases-140000500.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.